Between Q1 2021 and Q4 2025, bioeconomy startups raised $14.2 billion across 20 quarters. Quarterly investment grew from $208 million to $893 million — a 4.3x increase that outpaced nearly every other deep-tech category over the same period.

But the headline growth conceals a more interesting story. The sector composition of funding changed dramatically. Deal sizes evolved. Geographic concentration shifted. And the volatility of quarterly investment — a measure of asset class maturity — declined by 42%.

The Quarterly Picture

AgriTech consistently led, but its share of total funding declined from 39% in early 2021 to 30% by the end of 2025. Biomaterials and Synthetic Biology absorbed the difference, growing from a combined 29% to 42%. This sector rotation is a sign of a maturing asset class — capital follows proof points, and proof points in biomaterials (Carbios' 50K-ton plant, Bolt Threads' commercial products) and synbio (Ginkgo's Nebula platform, LanzaTech's six commercial plants) have accumulated.

Deal Size Evolution

The average deal size tells a story of growing conviction. In 2021-H1, the average Synthetic Biology deal was $3.8 million. By 2025-H2, it was $9.8 million — a 2.6x increase.

Across all sectors, average deal sizes roughly doubled. This is consistent with a pattern where early-stage companies survived the 2022-2023 correction and raised larger follow-on rounds as they approached commercial scale. The companies that didn't make it — Amyris (Chapter 11, 2023), many cultivated meat startups — are absent from the 2025 numbers.

---

Data Sources: PitchBook bioeconomy vertical data (2021-2025), Crunchbase bioeconomy startup funding, Synbiobeta funding reports, company press releases. Geographic analysis based on HQ location of lead investor.

About the Author: Martin DAVILA is a bioeconomy analyst and the founder of Bioinfometrics.